Register for our free email digests:
Latest From Ono Pharmaceutical Co. Ltd.
Scrip analyses the potential of "hot" immunotherapy mechanisms, such as PD-1 inhibitors and CAR-T therapies, in various stages of clinical development for glioblastoma.
Although South Korea has a good clinical trial infrastructure, workforce, and novel drug development technology, it still lacks the power to lead the development of new drugs across the finish line. The country needs to create an environment that can attract multinationals to co-research and co-develop drugs with domestic pharma firms under open innovation programs if Korea-originated blockbusters are ever to emerge, experts told a recent forum in Seoul.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2017.
French biotechs Servier and ILTOO sign an option agreement for the latter's IL-2 inhibitor for lupus, while Korean biotechs LegoChem and Bridge will team up in idiopathic pulmonary fibrosis.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.